PLM-101

CAT: 0804-HY-149539Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-149539Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) [1].
UNSPSC
12352005
Target
FLT3; RET
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/plm-101.html
Solubility
10 mM in DMSO
Smiles
FC1=CC2=C(C=C1)NC(/C2=C3NC4=CC=CC=C4C\3=N/OCCN5CCNCC5)=O
Molecular Formula
C22H22FN5O2
Molecular Weight
407.44
References & Citations
[1]Choi YJ, et al. PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia. Biomed Pharmacother. 2023 Sep;165:115066.. .
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-148034Plm IV inhibitor-1
HY-148035Plm IV inhibitor-2
HY-162278HSD17B13-IN-101
HY-P5642Retrocyclin-101
HY-168117HP-101
HY-117702RB 101
HY-116065CUMI-101
HY-10914-01UCPH-101
HY-18964-01MG-101
HY-157646-01MZ-101

Alternative Products

CatalogName
MBS5820532PLM-101
C45574-01PLM Antibody
PE-86697-01PLM Derived Peptide
RA34142-01PLM rabbit pAb
DF12021-01FXYD1/PLM Antibody
AF6786-BPFXYD1/PLM Peptide
abx025160-01PLM (pS68) Antibody
55-749M PLM Antibody
MBS9617889-01FXYD1/PLM Blocking Peptide
E45M02326G-4Phospho-PLM (S68) Antibody

Popular Products